‹< Latuda’s Pharmacology |
|US brand name: Latuda|
| Generic name: lurasidone |
Latuda was approved by the FDA to treat schizophrenia 28 October 2010 and bipolar depression 28 June 2013.
I’ve got to give props to Sunovion for how well the official Latuda site is geared towards the schizophrenic community, with families & caregivers as an adjunct, but still out in the open. In the way people with all sorts of brain cooties are encouraged to have a support network who aren’t afraid to be associated with them. Like similar well-made sites (e.g. the Invega Sustenna site), the Latuda site treats the schizophrenic as adults, able to read at a high-school level, and capable of making their own decisions when it comes to medication.
Now that Latuda has been approved to treat bipolar depression, the schizophrenia part of the site has been relegated to a subdirectory, with a small link to it on the all about bipolar home page. That’s not surprising. There’s a shitload more money in bipolar than there is in schizophrenia.
On the flip side, their site for health care professionals is creepy. Why? Compare the pictures of schizophrenic guy on both sites. If that is how some doctors see us, maybe they need to be taking 20mg of Latuda a day as well. On the plus side, Sunovion made available the results from the clinical trials that got Latuda FDA approval. While not as transparent as I’d like, it’s still better than nothing.
Latuda’s side effect profile is really odd. For a drug that kicks practically everyone’s ass at D2 (only some of the older APs like fluphenazine and thiothixene are more potent), and has the highest rates for movement disorders I’ve seen in a PI sheet, yet has, based on the information available so far, surprisingly little affect on prolactin, blood sugar, cholesterol, and triglycerides. I’m trying to wrap my head around that one. Maybe its (literally) shitty pharmacokinetics causes all that D2 action to bypass the pancreas and liver. Maybe it manages to exert its action at the serotonin receptors there much better than other APs, compensating for the D2 antagonism. Maybe some of both. Maybe it’s something else entirely - like Stahl’s “x-receptor,” an as-yet-discovered receptor, or property of a known receptor, that affects metabolic functions.
On the subject of side effects, here’s a great bit of refreshing honesty from a drug company:
Too bad the adverse reactions the R&D guys at Dainippon Sumitomo focused on were EPS and other movement disorders. Ooops. No wonder only a third of the people in the study completed it. And Latuda was approved in the US before Japan, where it was developed. Hell, it still isn’t approved in Japan (or anywhere else in Asia) to treat schizophrenia.
Name, Address, Serial Number (Generic and Overseas Availability)
Available in the US as a generic? No
Shapes & Sizes (How Supplied)
In the US:
- 20 mg round white tablets
- 40 mg round white tablets
- 60 mg oblong white tablets
- 80 mg oval pale green tablets
- 120 mg oval white tablets
An L and the dosage are stamped / carved / engraved / debossed on one side of the tablet.
For some reason in Europe and the UK they use freebase lurasidone, and not lurasidone HCl, as the active ingredient, so dosages are smaller.
Commie Metric European tablets come in 18.5, 37, and 74 mg strengths.
Other Trade Names and Overseas Availability
Not including controlled/extended/sustained release suffixes (Efexor ER, Trevilor retard e.g.) or branded generics that are a hyphenate of the generic name and the drug company name (Apo-Citalopram e.g.).
Lurasidone is sold as Latuda all over the world (so far). It is currently available in:
- the EU (but not Ireland1)
- Great Britain
Latuda is pending approval in:
Alternate INNs (because one is never enough)
- lurasidona - Spanish & Portuguese
- lurasidonum - Latin
Full US PI sheet, Global SPCs & PILs, Other Consumer Review & Rating Sites, and Other Sites that may be of Interest
Latuda’s Full US Prescribing Information / PI Sheet
Prescribing Information & Patient Information from Around the World
- UK Latuda SPC
- Canadian Latuda PM
- EU Latuda EPAR
- EU Latuda Assessment Report
- Equivalent to an FDA New Drug Approval (NDA), which is something you often need to file a Freedom of Information Act (FOIA) request to get (after a long-ass time) from the FDA. This contains all sorts of stuff drug companies don’t like the public seeing, like:
- data from animal tests that involve “sacrificing” monkeys and dogs
- reports of people who died during clinical trials, even though it’s really obvious their deaths had absolutely nothing to do with the drugs being tested
- So I can actually understand why Big Pharma doesn’t want a bunch of shrill antipsychiatry dildos getting a hold of such things to take out of context.
- As they’ll just make up that sort of shit anyway, so you may as well make everything available to show that reality, while unfortunate, is much less bad than what the Breggins and their Scientology suck-ups make up.
Consumer Review Sites
Other Sites of Interest
If you have any questions not answered here, please see the Crazymeds Latuda discussion board.
- Latuda Full US Prescribing Information
- UK Latuda SPC
- Stahl, Stephen M. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (Essential Psychopharmacology Series) Third edition Cambridge University Press 2008. ISBN:978–0521673761
- Stahl, Stephen M. and Laurence Mignon Stahl’s Illustrated Antipsychotics: Treating Psychosis, Mania and Depression 2010 Cambridge University Press.
- Yasui-Furukori, Norio “Update on the development of lurasidone as a treatment for patients with acute schizophrenia.” Drug Design, Development and Therapy 2012; 6: 107–115. Published online May 8, 2012.
- Cruz, Martin P. “Lurasidone HCl (latuda), an oral, once-daily atypical antipsychotic agent for the treatment of patients with schizophrenia.” Pharmacy and Therapeutics 36.8 (2011): 489.
- Citrome, Leslie. “Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic.” Clinical schizophrenia & related psychoses 4.4 (2011): 251-257.
- Meltzer, Herbert Y., Josephine Cucchiaro, Robert Silva, Masaaki Ogasa, Debra Phillips, Jane Xu, Amir H. Kalali, Edward Schweizer, Andrei Pikalov, and Antony Loebel. “Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled study.” American Journal of Psychiatry 168, no. 9 (2011): 957-967.
- Samalin, Ludovic, Marion Garnier, and Pierre-Michel Llorca. “Clinical potential of lurasidone in the management of schizophrenia.” Therapeutics and clinical risk management 7 (2011): 239. Published online Jun 27, 2011
- Ishibashi, Tadashi, Tomoko Horisawa, Kumiko Tokuda, Takeo Ishiyama, Masaaki Ogasa, Rie Tagashira, Kenji Matsumoto et al. “Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.” Journal of Pharmacology and Experimental Therapeutics 334, no. 1 (2010): 171-181. Published online April 19, 2010.
- Kato, Masaki, and Chia-Ming Chang. “Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.” CNS drugs 27.1 (2013): 11-19. Published online 25 May 2013
‹< Latuda’s Pharmacology |
Pages and Forum Topics Google Thinks are Relevant to Your Mental Health
||Keep Crazymeds on the air.
Donate some spare electronic currency
you have floating around The Cloud
1 Which is fucking hilarious, because Latuda is manufactured in Ireland for distribution to
those commies the rest of Europe.
|Last modified on Wed, 04 May, 2016 at 17:23:40 by JerodPoore||Page Author Jerod Poore||Date created Tuesday, 14 May 2013 at 09:18:44|
|“Latuda (lurasidone): Availability, Comments, Links, More” by Jerod Poore is copyright © 2013 Jerod Poore ||Published online 2013/05/14|
Latuda, and all other drug names on this page and used throughout the site, are the trademarks of someone else. Latuda’s PI Sheet will probably have the name of the manufacturer and trademark owner (they’re not always the same company) at or near the very bottom. Or ask Google who the owner is. The way pharmaceutical companies buy each other and swap products like Monopoly™ real estate, the ownership of the trademark may have changed without my noticing. It may of changed hands by the time you finished reading this article.
Page design and explanatory material by Jerod Poore, copyright © 2003 - 2016. All rights reserved. See the full copyright notice for full copyright details.
Don’t automatically believe everything you read on teh Intergoogles. No warranty is expressed or implied in this information. Consult one or more doctors and/or pharmacists before taking, or changing how you take any neurological and/or psychiatric medication. Your mileage may vary. What happened to us won’t necessarily happen to you. For more details see the Crazymeds big-ass disclaimer.
Enable Crazymeds’ Financial Solvency!
Enable Crazymeds to keep spreading our knowledge. Donate some spare e-currency you have floating around The Cloud.
Improve Your Social Media Skills
Sites That Probably Suck Less Than Crazymeds
Community, Info & Support